within Pharmacolibrary.Drugs.ATC.N;

model N05CJ01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.82,
    Cl             = 1.03 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0.0492,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010516666666666667,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Suvorexant is an orally active dual orexin receptor antagonist used for the treatment of insomnia. It is approved by the FDA and other regulatory agencies for adult patients who have difficulties with sleep onset and/or sleep maintenance.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following a single oral dose under fasted conditions.</p><h4>References</h4><ol><li><p>Wrishko, RE, McCrea, JB, Yee, KL, Liu, W, Panebianco, D, Mangin, E, Chakravarthy, M, Martinez-Cantarin, MP, &amp; Kraft, WK (2019). Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. <i>Clinical drug investigation</i> 39(5) 441–451. DOI:<a href=&quot;https://doi.org/10.1007/s40261-019-00764-x&quot;>10.1007/s40261-019-00764-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30810914/&quot;>https://pubmed.ncbi.nlm.nih.gov/30810914</a></p></li><li><p>Neubauer, DN (2014). New and emerging pharmacotherapeutic approaches for insomnia. <i>International review of psychiatry (Abingdon, England)</i> 26(2) 214–224. DOI:<a href=&quot;https://doi.org/10.3109/09540261.2014.888990&quot;>10.3109/09540261.2014.888990</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24892896/&quot;>https://pubmed.ncbi.nlm.nih.gov/24892896</a></p></li><li><p>Cui, D, Cabalu, T, Yee, KL, Small, J, Li, X, Liu, B, Maciolek, C, Smith, S, Liu, W, McCrea, JB, &amp; Prueksaritanont, T (2016). In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 46(10) 882–895. DOI:<a href=&quot;https://doi.org/10.3109/00498254.2015.1129565&quot;>10.3109/00498254.2015.1129565</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26864332/&quot;>https://pubmed.ncbi.nlm.nih.gov/26864332</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05CJ01;
